Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Eisai Begins FDA Rolling Submission for Leqembi SC for Starting Dose
Eisai has begun a rolling submission to the US FDA seeking approval for the use of a subcutaneous autoinjector version of Leqembi (lecanemab) as a once-weekly dosing option beginning from the initiation phase of treatment. The filing is being made…
To read the full story
Related Article
- FDA Delays Review of Leqembi Iqlik for Alzheimer’s Initiation Therapy
May 11, 2026
- Leqembi Iqlik Now under FDA Review for Initiation Phase
January 26, 2026
- Rolling Submission for Leqembi SC Starting Dose Completed in US
November 27, 2025
- Leqembi Iqlik Autoinjector Now Available in US: Eisai/Biogen
October 8, 2025
- FDA Clears Leqembi Autoinjector; Launch Set for Oct. 6
September 2, 2025
- FDA Accepts Leqembi SC for Review; Target Date Set to Aug. 31
January 15, 2025
- FDA Rolling Submission for Leqembi SC Completed: Eisai
November 5, 2024
- Eisai Begins Rolling Submission for Subcutaneous Leqembi in US
May 16, 2024
BUSINESS
- Kissei Urges Halt to New Tavneos Use after Fatal Liver Injury Reports
May 18, 2026
- Eisai Hits Record Sales as Leqembi Revenue Nearly Doubles in FY2025
May 18, 2026
- Kaken Files Vascular Malformation Drug in Japan, Eyes FY2027 Approval
May 18, 2026
- Regenxbio Appeals FDA CRL for MPS II Gene Therapy RGX-121
May 18, 2026
- Fuji Sees New Bio-AG Pricing Rules as Tailwind for Biosimilars
May 18, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…